Nakul P Valsangkar1, Thun Ingkakul1, Camilo Correa-Gallego1, Mari Mino-Kenudson2, Ricard Masia2, Keith D Lillemoe1, Carlos Fernández-del Castillo1, Andrew L Warshaw1, Andrew S Liss1, Sarah P Thayer3. 1. Department of Surgery, Andrew L. Warshaw, M.D. Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 2. Department of Pathology, Andrew L. Warshaw, M.D. Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA. 3. Department of Surgery, Andrew L. Warshaw, M.D. Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address: sarah.thayer@unmc.edu.
Abstract
OBJECTIVE: The prognosis of ampullary adenocarcinoma (AA) usually is favorable; however, a subset of AA have poor biology and outcomes similar to pancreatic cancer. Patients in this subset will have early recurrence and death usually within 2 years. To date, there are no genetic markers to identify these patients. This study identifies the high-risk subset of AA and evaluates the mutational status of KRAS in predicting poor outcome. METHODS: The tumor registry of an academic center was reviewed for data on patients managed operatively with AA. KRAS genotypes were determined for these patients using a polymerase chain reaction-based assay on clinical specimens. Analysis of variance and χ(2) tests was used to categorize continuous and categorical variables. Univariate and multivariate survival analyses were performed using Kaplan-Meier and Cox methods, respectively. RESULTS: A total of 146 patients were identified with AA between 1982 and 2008. After stringent pathologic review, 97 patients were confirmed with AA, of whom 75 had tissue specimens available for analysis. Genotyping revealed 67% were wild-type (KRAS(WT)), and 33% were mutant for KRAS. Patients with KRAS(G12D) (n = 9), the most common mutational genotype, had poorer median survival (62 months) compared with those with KRAS(non-G12D) mutants (median survival not reached, mean 145 months) and KRAS(WT) patients (155 months, P = .05). Patients with survival ≤30 months were labeled "high-risk." Of the 9 patients with KRAS(G12D), 56% were in this high-risk subset, compared with 18% of KRAS(WT) (P = .02) and 31% of KRAS(non-G12D) (P > .05) populations. Patients with KRAS(G12D) also were more likely to present with advanced T stage. CONCLUSION: The KRAS(G12D) mutation identifies a subset of AA patients with poor prognoses and may be used to identify patients at risk of early recurrence and poorer survival who may benefit from adjuvant therapy.
OBJECTIVE: The prognosis of ampullary adenocarcinoma (AA) usually is favorable; however, a subset of AA have poor biology and outcomes similar to pancreatic cancer. Patients in this subset will have early recurrence and death usually within 2 years. To date, there are no genetic markers to identify these patients. This study identifies the high-risk subset of AA and evaluates the mutational status of KRAS in predicting poor outcome. METHODS: The tumor registry of an academic center was reviewed for data on patients managed operatively with AA. KRAS genotypes were determined for these patients using a polymerase chain reaction-based assay on clinical specimens. Analysis of variance and χ(2) tests was used to categorize continuous and categorical variables. Univariate and multivariate survival analyses were performed using Kaplan-Meier and Cox methods, respectively. RESULTS: A total of 146 patients were identified with AA between 1982 and 2008. After stringent pathologic review, 97 patients were confirmed with AA, of whom 75 had tissue specimens available for analysis. Genotyping revealed 67% were wild-type (KRAS(WT)), and 33% were mutant for KRAS. Patients with KRAS(G12D) (n = 9), the most common mutational genotype, had poorer median survival (62 months) compared with those with KRAS(non-G12D) mutants (median survival not reached, mean 145 months) and KRAS(WT) patients (155 months, P = .05). Patients with survival ≤30 months were labeled "high-risk." Of the 9 patients with KRAS(G12D), 56% were in this high-risk subset, compared with 18% of KRAS(WT) (P = .02) and 31% of KRAS(non-G12D) (P > .05) populations. Patients with KRAS(G12D) also were more likely to present with advanced T stage. CONCLUSION: The KRAS(G12D) mutation identifies a subset of AA patients with poor prognoses and may be used to identify patients at risk of early recurrence and poorer survival who may benefit from adjuvant therapy.
Authors: Bret Taback; Anton J Bilchik; Sukamal Saha; Takahiro Nakayama; David A Wiese; Roderick R Turner; Christine T Kuo; Dave S B Hoon Journal: Int J Cancer Date: 2004-09-01 Impact factor: 7.396
Authors: C H Chung; R E Wilentz; M M Polak; T B Ramsoekh; L A Noorduyn; D J Gouma; K Huibregtse; G J Offerhaus; R J Slebos Journal: J Clin Pathol Date: 1996-06 Impact factor: 3.411
Authors: B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos Journal: N Engl J Med Date: 1988-09-01 Impact factor: 91.245
Authors: A Font; A Abad; M Monzó; J J Sanchez; M Guillot; J L Manzano; M Piñol; I Ojanguren; R Rosell Journal: Dis Colon Rectum Date: 2001-04 Impact factor: 4.585
Authors: J M Siegfried; A T Gillespie; R Mera; T J Casey; P Keohavong; J R Testa; J D Hunt Journal: Cancer Epidemiol Biomarkers Prev Date: 1997-10 Impact factor: 4.254
Authors: P Keohavong; M A DeMichele; A C Melacrinos; R J Landreneau; R J Weyant; J M Siegfried Journal: Clin Cancer Res Date: 1996-02 Impact factor: 12.531
Authors: Brett L Ecker; Charles M Vollmer; Stephen W Behrman; Valentina Allegrini; John Aversa; Chad G Ball; Courtney E Barrows; Adam C Berger; Martha N Cagigas; John D Christein; Elijah Dixon; William E Fisher; Mollie Freedman-Weiss; Francisco Guzman-Pruneda; Robert H Hollis; Michael G House; Tara S Kent; Stacy J Kowalsky; Giuseppe Malleo; Ronald R Salem; Roberto Salvia; Carl R Schmidt; Thomas F Seykora; Richard Zheng; Amer H Zureikat; Paxton V Dickson Journal: JAMA Surg Date: 2019-08-01 Impact factor: 14.766
Authors: Birte Kulemann; Andrew S Liss; Andrew L Warshaw; Sindy Seifert; Peter Bronsert; Torben Glatz; Martha B Pitman; Jens Hoeppner Journal: Tumour Biol Date: 2015-12-18
Authors: Suguru Yamashita; Michael J Overman; Huamin Wang; Jun Zhao; Masayuki Okuno; Claire Goumard; Ching-Wei Tzeng; Michael Kim; Jason B Fleming; Jean-Nicolas Vauthey; Matthew H Katz; Jeffrey E Lee; Claudius Conrad Journal: Ann Surg Oncol Date: 2017-10-04 Impact factor: 5.344